Amylyx Pharmaceuticals AMLX

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.27 (+7.48%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Amylyx Pharmaceuticals (AMLX)
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $3.87

  • Market Cap

    $342.89 Million

  • Price-Earnings Ratio

    -0.87

  • Total Outstanding Shares

    88.60 Million Shares

  • Total Employees

    123

  • Dividend

    $0.42 Per Share Quarterly

  • IPO Date

    January 7, 2022

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    43 thorndike street, Cambridge, MA, 02141

  • Homepage

    https://www.amylyx.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

January 1, 2024 to December 31, 2024
MetricValue
Net Cash Flow From Financing Activities, Continuing$348,000
Net Cash Flow From Operating Activities$-167.65 Million
Net Cash Flow From Operating Activities, Continuing$-167.65 Million
Net Cash Flow From Financing Activities$348,000
Net Cash Flow$-92.08 Million
Exchange Gains/Losses$-438,000

Income Statement

January 1, 2024 to December 31, 2024
MetricValue
Diluted Earnings Per Share$-4.43
Cost Of Revenue$5.95 Million
Net Income/Loss Attributable To Noncontrolling Interest$0
Benefits Costs and Expenses$389.51 Million
Other Operating Expenses$177.73 Million
Diluted Average Shares$68.14 Million

Comprehensive Income

January 1, 2024 to December 31, 2024
MetricValue
Comprehensive Income/Loss Attributable To Parent$-302.03 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Comprehensive Income/Loss$-302.03 Million
Other Comprehensive Income/Loss$-289,000
Other Comprehensive Income/Loss Attributable To Parent$-289,000

Balance Sheet

January 1, 2024 to December 31, 2024
MetricValue
Equity$164.76 Million
Noncurrent Assets$4.20 Million
Equity Attributable To Parent$164.76 Million
Current Assets$189.43 Million
Noncurrent Liabilities$463,000
Fixed Assets$961,000

Historical Dividends

Current dividend: $0.42 Per Share Quarterly
Announcement DatePayment DateRecord DateAmountFrequency
Jan 25, 2018Apr 2, 2018Mar 29, 2018$0.41965Quarterly
Dec 27, 2017Jan 2, 2018Dec 29, 2017$0.3556285Quarterly

Recent Headlines From The Web

Latest news, press releases, and media coverage about AMLX from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.